uniQure NVQURE +0.12%50 Days Payable is 1,993.54 as of Mar. 2026, which is 747% above its 10-year median of 235.29. GuruFocus rates QURE with a GF Score™ of 50/100 and a GF Value™ of $6.00 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 700 Biotechnology companies, uniQure NV ranks better than 87.43% on this metric.
uniQure NV's average Accounts Payable for the
three
months ended in Mar. 2026 was $4.78 Mil. uniQure NV's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.22 Mil.
Hence, uniQure NV's Days Payable for the
three
months ended in Mar. 2026 was 1,993.54.
The historical rank and industry rank for uniQure NV's Days Payable or its related term are showing as below:
QURE'
s Days Payable Range Over the Past 10 Years
Min: 45.84 Med: 235.29 Max: 1341.91
Current: 1137.14
During the past 13 years, uniQure NV's highest Days Payable was 1341.91. The lowest was 45.84. And the median was 235.29.
QURE's Days Payable is ranked better than 87.43% of 700
companies
in the Biotechnology industry
Industry Median: 113.1
vs QURE: 1137.14
uniQure NV's Days Payable
declined
from Mar. 2025 (2,893.83) to Mar. 2026 (1,993.54).
It may suggest that uniQure NVaccelerated paying its suppliers.
uniQure NV Days Payable Related Terms
uniQure NV Days Payable Historical Data
* Premium members only.
The historical data trend for uniQure NV's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, uniQure NV's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
uniQure NV Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, uniQure NV's Days Payable distribution charts can be found below:
* The bar in red indicates where uniQure NV's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
uniQure NV's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
uniQure NV (QURE) has a Days Payable of 1,993.54 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on uniQure NV and its competitors. This is 747% above median its historical median of 235.29. Over the past decade, uniQure NV's Days Payable has ranged from 45.84 to 1,341.91. According to the industry distribution chart, uniQure NV ranks #88 out of 700 companies in the Biotechnology industry, placing it in the top 12.6%.
Is uniQure NV's Days Payable too high?
uniQure NV's current Days Payable of 1,993.54 is 747% above median its 10-year median of 235.29. Over the past 10 years, this metric has ranged from a low of 45.84 to a high of 1,341.91. The Biotechnology industry median Days Payable is 113.10. uniQure NV's value of 1,993.54 is 1662.6% above this industry median. Based on the distribution chart, uniQure NV ranks #88 out of 700 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, uniQure NV has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's Days Payable compare to ALMS and ARQT?
According to the Biotechnology industry distribution chart, uniQure NV ranks #88 out of 700 companies for Days Payable. This places uniQure NV in the top 13% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.10. uniQure NV's value of 1,993.54 is 1662.6% above this benchmark. Historically, uniQure NV's own Days Payable has ranged from 45.84 to 1,341.91 over the past decade. While the company's 10-year median is 235.29 vs. the industry median of 113.10, uniQure NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. uniQure NV's current Days Payable of 1,993.54 is 1662.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on uniQure NV and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. uniQure NV's current Days Payable is 1,993.54, which is 747% above median its own 10-year median of 235.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (QURE) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.00, compared to a current price of $41.41 — trading 590.2% above its estimated fair value. The current Days Payable is 1,993.54, which is 747% above median its 10-year median of 235.29 and 1662.6% above the Biotechnology industry median of 113.10. uniQure NV's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For uniQure NV (QURE), the current Days Payable is 1,993.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is uniQure NV (QURE) Overvalued in 2026?
Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued.
The current stock price of $41.41 is trading 590.2% above its estimated GF Value™ of $6.00.
GuruFocus considers uniQure NV to be Significantly Overvalued.
Key valuation signals for QURE:
Days Payable: 1,993.54 (747% above median its 10-year median of 235.29)
GF Value™: $6.00 vs. price of $41.41 (590.2% above fair value)
Industry Position: 1662.6% above the Biotechnology median (#88 of 700)
No single metric tells the full story. See the QURE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
50GF Score
Get the complete analysis for QURE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
QURE has been successfully added to your 
